CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population

Pharmacogenetics and Genomics

Volumn 17, Issue 7, 2007, Pages 461-471

  Saito, Yoshiro ^a   Katori, Noriko ^a   Soyama, Akiko ^a   Nakajima, Yukiko ^a   Yoshitani, Takashi ^a   Kim, Su Ryang ^a   Fukushima Uesaka, Hiromi ^a   Kurose, Kouichi ^a   Kaniwa, Nahoko ^a   Ozawa, Shogo ^a   Kamatani, Naoyuki ^b   Komamura, Kazuo ^g   Kamakura, Shiro ^g   Kitakaze, Masafumi ^g   Tomoike, Hitonobu ^g   Sugai, Kenji ^c   Minami, Narihiro ^c,d   Kimura, Hideo ^d   Goto, Yu Ichi ^d   Minami, Hironobu ^h   Yoshida, Teruhiko ^e   Kunitoh, Hideo ^f   Ohe, Yuichiro ^f   Yamamoto, Noboru ^f   Tamura, Tomohide ^f   Saijo, Nagahiro ^h   Sawada, Jun Ichi ^a   more..

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c National Center of Neurology and Psychiatry   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

^e NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^h NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

CYP2C8; Haplotype; Paclitaxel; Pharmacokinetics

Indexed keywords

ANTIALLERGIC AGENT; CARBOPLATIN; CYTOCHROME P450 2C8; DEXAMETHASONE; NEDAPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER; CLINICAL TRIAL; DRUG CLEARANCE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE STRUCTURE; GENETIC VARIABILITY; HAPLOTYPE; HETEROZYGOSITY; HUMAN; JAPANESE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; THYMUS CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; DNA PRIMERS; FEMALE; GENETICS, POPULATION; HAPLOTYPES; HUMANS; JAPAN; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; PHARMACOGENETICS; VARIATION (GENETICS);

EID: 34250173817     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32805b72c1     Document Type: Article

References (21)

1. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005; 77:341-352.
2. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275:566-575.
3. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48:424-432.
4. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 2001; 11:597-607.
5. Soyama A, Saito Y, Hanioka N, Murayama N, Nakajima O, Katori N, et al. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull 2001; 24:1427-1430.
6. Bahadur N, Leathart JB, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 2002; 64:1579-1589.
7. Soyama A, Saito Y, Komamura K, Ueno K, Kamakura S, Ozawa S, et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 2002; 17:374-377.
8. Hichiya H, Tanaka-Kagawa T, Soyama A, Jinno H, Koyano S, Katori N, et al. Functional characterization of five novel CYP2C8 variants, G171S, R186X, R186G, K247R, and K383N, found in a Japanese population. Drug Metab Dispos 2005; 33:630-636.
9. Nakajima Y, Yoshitani T, Fukushima-Uesaka H, Saito Y, Kaniwa N, Kurose K, et al. Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese cancer patients. Clin Pharmacol Ther 2006; 80:179-191.
10. Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 2005; 59:62-68.
11. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 2003; 74:380-387.
12. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K, et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005; 11:8097-8104.
13. Nakajima M, Fujiki Y, Noda K, Ohtsuka H, Ohkuni H, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1. J Clin Pharmacol 2005; 45:674-682.
14. Judson R, Stephens JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 2000; 1:15-26.
15. Monsarrat B, Chatelut E, Royer I, Alvinerie P, Dubois J, Dezeuse A, et al. Modification of paclitaxel metabolism in a cancer patient by induction of cytochrome P450 3A4. Drug Metab Dispos 1998; 26:229-233.
16. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S, et al. Utilization of human liver microsomes to explain individual differences in paclitaxel metabolism by CYP2C8 and CYP3A4. J Pharmacol Sci 2005; 97:83-90.
17. Ferguson SS, Chen Y, LeCluyse EL, Negishi M, Goldstein JA. Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnanex receptor, glucocorticoid receptor, and hepatic nuclear factor 4α. Mol Pharmacol 2005; 68:747-757.
18. Kitamura Y, Moriguchi M, Kaneko H, Morisaki H, Morisaki T, Toyama K, et al. Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm. Ann Hum Genet 2002; 66:183-193.
19. Bandelt HJ, Forster P, Rohl A. Median-joining networks for inferring intraspecific phylogenies. Mol Biol Evol 1999; 16:37-48.
20. Lehnert M, Emerson S, Dalton WS, de Giuli R, Salmon SE. In vitro evaluation of chemosensitizers for clinical reversal of P-glycoprotein- associated Taxol resistance. J Natl Cancer Inst Monogr 1993; 15:63-67.
21. Roscigno RF, Weiner M, Garcia-Blanco MA. A mutational analysis of the polypyrimidine tract of introns. Effects of sequence differences in pyrimidine tracts on splicing. J Biol Chem 1993; 268:11222-11229.